FBRX Forte Biosciences, Inc.
USHealthcareAs of 2026-08-24
Why FBRX matters now
Forte Biosciences, Inc. (FBRX) is a US stock in Healthcare. The latest InvestLog snapshot shows $76.95 with +0.04% on the session and $1.58B in market capitalization; recent performance reads 1-month -11.06% and YTD -34.54%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-22.1M, and EPS of $-1.24. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -24.0%.
The latest indexable market news headline is "Are SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders?" from GuruFocus.
Additional event context on this page matters because analyst consensus is Buy with a median target of $65.00; recent insider activity includes Wagner Paul A. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
75.63
P/S
0.00
EV/EBITDA
-2.55
DCF Value
$0.47
FCF Yield
-24.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-106.2%
ROA
-112.8%
ROIC
-176.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-22.1M | $-1.24 |
| Q4 2025 | $0.00 | $-24.8M | $-1.39 |
| FY 2025 | $0.00 | $-69.4M | $-4.71 |
| Q3 2025 | $0.00 | $-17.7M | $-0.99 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$65.00
Target (Median)
$65.00
Target Range
$65.00 - $65.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.87
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.